A comprehensive analysis of liver safety across zibotentan oncology trials: knowledge of the past offers new perspectives on the present

CONCLUSIONS: We found no evidence of zibotentan-related liver biochemistry changes among cancer-treated patients, suggesting that hepatotoxicity of ERAs is molecule-dependent, and allowing exploration of zibotentan for new indications.PMID:38469902 | DOI:10.1080/14740338.2024.2328816

Source: Expert Opinion on Drug Safety - March 12, 2024 Category: Drugs & Pharmacology Authors: Anna Fettiplace Sherri Matis-Mitchell Oleksandr Molodetskyi Malin S öderbergh Jan Oscarsson Min Lin Srivathsa Ravikiran Martin Billger Philip Ambery Source Type: research